Regulation of integrin activity and signalling  by Gahmberg, Carl G. et al.
Biochimica et Biophysica Acta 1790 (2009) 431–444
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbagenReview
Regulation of integrin activity and signalling
Carl G. Gahmberg a,⁎, Susanna C. Fagerholm b, Susanna M. Nurmi a, Triantafyllos Chavakis c,
Silvia Marchesan a, Mikaela Grönholm a
a Division of Biochemistry, Faculty of Biosciences, University of Helsinki, Viikinkaari 5, 00014, Finland
b Division of Pathology and Neuroscience, Ninewells Hospital and Medical School, University of Dundee, UK
c Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA⁎ Corresponding author.
E-mail address: Carl.Gahmberg@helsinki.ﬁ (C.G. Gah
0304-4165 © 2009 Elsevier B.V.
doi:10.1016/j.bbagen.2009.03.007
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 22 December 2008
Received in revised form 5 March 2009
Accepted 10 March 2009
Available online 14 March 2009
Keywords:
Leukocyte
Signalling
Integrin
LFA-1
PhosphorylationThe ability of cells to attach to each other and to the extracellular matrix is of pivotal signiﬁcance for the
formation of functional organs and for the distribution of cells in the body. Several molecular families of
proteins are involved in adhesion, and recent work has substantially improved our understanding of their
structures and functions. Also, these molecules are now being targeted in the ﬁght against disease. However,
less is known about how their activity is regulated. It is apparent that among the different classes of adhesion
molecules, the integrin family of adhesion receptors is unique in the sense that they constitute a large group
of widely distributed receptors, they are unusually complex and most importantly their activities are strictly
regulated from the inside of the cell. The activity regulation is achieved by a complex interplay of cytoskeletal
proteins, protein kinases, phosphatases, small G proteins and adaptor proteins. Obviously, we are only in the
beginning of our understanding of how the integrins function, but already now fascinating details have
become apparent. Here, we describe recent progress in the ﬁeld, concentrating mainly on mechanistical and
structural studies of integrin regulation. Due to the large number of articles dealing with integrins, we focus
on what we think are the most exciting and rewarding directions of contemporary research on cell adhesion
and integrins.
© 2009 Elsevier B.V.Open access under CC BY-NC-ND license.1. IntroductionResearch on cell adhesion is one of the most rapidly expanding
ﬁelds in the biological and biomedical sciences. One reason for this is
the realisation that cell adhesion is involved in many essential normal
cellular and pathological functions including the formation of
complex organs, the dissemination of blood cells into tissues during
host defence, in inﬂammatory disorders, and the release of metastatic
cells from malignant tumors and their attachment to secondary
organs. Another reason is the fact that recent methodological progress
has enabled us to increasingly deepen our understanding of the
organisation of complex cellular systems and their regulation. Several
excellent reviews have been written on adhesion and on the major
molecular families of adhesionmolecules. These include the integrins,
the cadherins [1], the selectins [2], the adhesion-G protein-coupled
receptors [3], the extracellular matrix proteins such as ﬁbronectin [4],
collagens, and laminins, and the large immunoglobulin superfamily of
adhesion molecules [5,6].
In particular, the integrin family of adhesion molecules is drawing
increasing attention. Integrins are fascinating molecules. They are
present in all nucleated cells, often in large numbers and many
members can be expressed simultaneously in a given cell. They aremberg).
-NC-ND license.structurally unusually complex and, importantly, they can act as
signalling molecules in both directions across the plasma membrane.
Although excellent reviews have been written on integrins including
structural and signalling aspects of these molecules [7–12], the ﬁeld
has becomemore andmore difﬁcult tomaster due to the large amount
of published studies on this subject. Therefore, in this review we
describe the most recent developments in the ﬁeld, how integrin
activity is regulated, and how integrins are able to signal in both
directions across the plasma membrane. We have mainly focused on
structural aspects of integrin regulation, and how intracellular
molecules bind to integrin tails and regulate integrin activity.
Although current knowledge is certainly still in its infancy or early
youth, we begin to get a glimpse of what integrins look like and how
they may function.
Integrins are present in metazoa and sponges, and primitive
bilateralia express integrins [8]. For example, Caenorhabditis elegans
has two integrins, but the number is substantially higher in more
developed organisms. In humans there are 24 different integrins,
which arise from the noncovalent association between one of each 18
α-subunits and 8 β-subunits (Fig. 1). Importantly, some subunits can
combine with several different partners, adding to the structural
complexity of integrin receptors. Using knockout mice it has become
evident that the integrins possess both redundant and nonredundant
functions, and that lack of expression may result in a wide variety of
effects ranging from blockage in preimplantation to embryonic or
Fig. 1. The integrin superfamily. The integrins can be subdivided according to their β
chains but note that some α chains can combine with several β chains. 24 different
integrins are present in humans.
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a natural human knockout is the leukocyte adhesion deﬁciency
syndrome (LAD-I) where mutations in the β2 integrin chain impair
leukocyte functions resulting in severe microbial infections, impaired
wound healing, defects in phagocytosis and chemotaxis [13,14].
Integrins are not alone in the plasma membrane. We are just
starting to appreciate the fact that often they are part of macro-
molecular assemblies required for proper signalling. One recent
example is the complex between the leukocyteMac-1 (αMβ2) integrin
and matrix metalloproteases [15,16]. Interestingly, the β2 integrin
complexes with matrix metalloproteases can be disrupted with
peptides, which interfere with the binding between the integrins
and the metalloproteases and these peptides efﬁciently inhibit
integrin activity [15,16]. The integrin polypeptides interact on the
outside of the cell, but also lateral associations in the transmembrane
regions of integrins [17] are important, although less is known about
them. Adding to the complexity is the fact that many of these
interactions are short-lived and therefore difﬁcult to study.
Integrins communicate over the plasma membrane in both
directions and we distinguish between outside-in and inside-out
signalling [18,19]. In outside-in signalling through integrins, ligands
bind to extracellular integrin domains, where a conformational
change occurs so that the signal is transmitted into the cell.
Furthermore, also integrin clustering may occur. Inside-out signalling
originates from non-integrin cell surface receptors or cytoplasmic
molecules and it activates signalling pathways inside the cells,
ultimately resulting in the activation/deactivation of integrins. In
this case, adhesion may be regulated both by conformational changes
in the integrin and by valency change (integrin clustering). In fact, this
division into two distinct signalling entities may not be that black and
white, instead both signalling events may occur simultaneously and
reinforce each other (see below).
In order to understand signalling dynamics, it is absolutely
necessary to have a good knowledge of integrin structure. Let us
therefore ﬁrst describe how integrins are constructed.
2. Integrin structure
2.1. The extracellular part of integrins — structural insights
All integrins are type I integral membrane proteins consisting of an
α- and a β-subunit forming a heterodimer [20]. In effect, the integrin
has a ligand binding “head” on the top of two “legs”. Fig. 2A shows asequence-based schematic drawing of the leukocyte LFA-1 (αLβ2,
CD11a/CD18) molecule, which may serve as a well studied example.
LFA-1 belongs to the integrins which have an inserted (I) domain, also
called von Willebrand factor (A) domain in the α chain. In the
integrins which have an I-domain (see Fig. 1), this is the primary
ligand binding region, whereas in integrins which lack the α chain I-
domain, the binding site in the integrin “head” is formed by structural
contributions of both theα and β chains [21]. The I-domain is inserted
in a G protein-like seven-bladed β-propeller domain [22]. This is
followed by an Ig-like “thigh”, two β-sandwich “calf”, a transmem-
brane and a cytoplasmic domain. The β polypeptide consists of a PSI
(plexin-semaphorin-integrin)-domain, a β I-like domain, an Ig-like
hybrid domain, 4 EGF-like domains, a “β-tail”, a transmembrane
domain and a cytoplasmic tail [21].
The integrins form well-deﬁned domains, and the ﬁrst integrin
I-domain to be crystallised was from Mac-1 (αM or CD11b) [23]
(Fig. 2B, C). The I-domain can exist in two different conformations: an
“open” (high afﬁnity) and a “closed” (low afﬁnity) conformation. An
important feature is the presence of the “MIDAS” (Metal Ion
Dependent Adhesion Site), which coordinates divalent metal cations,
required for the integrin high afﬁnity state. This is in agreement with
the fact that the ﬁrst crystal structure attributed to the “open” (high
afﬁnity) conformation displayed the MIDAS occupied by amagnesium
ion (Fig. 2C), while the structure attributed to the “closed” (low
afﬁnity) conformation did not have any cation bound at the MIDAS
(Fig. 2B). Nevertheless, subsequent studies led to the conclusion that
the MIDAS is likely to be constitutively occupied by a divalent
magnesium ion under physiological conditions, and that the metal
binding is not correlated per sewith the transition from closed to open
[24].
A remarkable difference between the ﬁrst two CD11b I-domain
structures (Figs. 2B and C) regards the position of the α7 helix, which
in the “closed” conformation is ﬁxed to the central β-sheet (Fig. 2B),
while upon activation it is displaced by a downward movement
leading to the “open” conformation (Fig. 2C). The metal is now
coordinated to six ligands: two serines of a DxSxS motif (x is any
amino acid) from the α1 loop; one threonine from the loop between
the α3 and α4 helices; two water molecules, of which one is hydrogen
bound to two aspartate residues (one from the DxSxS motif, and one
from the α5 loop). The sixth ligand is probably another molecule of
water, although in the crystal structure this position is occupied by a
glutamate from a neighbouring I-domain [23].
Another interesting structural feature is the β chain I-like domain.
Crystallographic studies show that in integrins, which lack theα chain
I-domain, the β I-like domain is the primary ligand binding site. It
contains three metal binding sites: the MIDAS, the ADMIDAS
(adjacent to the MIDAS), and the LIMBS (Ligand Induced Metal
Binding Site). In the physiologic low afﬁnity state, all three metal
binding sites are occupied: the MIDAS by a magnesium ion, while the
other two metal binding sites can be occupied by calcium ions [25].
However, this result is in contrast with previous studies that showed
only one metal present in the absence of ligand [26]. The magnesium
ion at MIDAS directly coordinates the aspartic acid residue of the RGD
ligands (the major binding motif in many integrin ligands), which
otherwise would be electrostatically repelled by the anionic residues
of the MIDAS itself [25]. Besides its known regulatory role, the
ADMIDAS calcium ion can be involved in ligand binding [27].
No complete type I integral membrane proteins have been
crystallised so far, and there is no structural information on whole
molecules. However, several crystal structures are available for the
extracellular portion of type I membrane proteins, produced as
recombinant chimeras, or obtained through protease cleavage.
A major breakthrough in integrin research occurred when the
external portion of the αvβ3 integrin was crystallised in its unbound
state. The most surprising fact was that the integrin ligand binding
head was turned towards the legs forming a V-like structure (Fig. 2D,
Fig. 2. Structures of integrins and their extracellular domains. A, Schematic drawing of the LFA-1 integrin. Note that the α I-domain is within the β-propeller, and the β I-like domain
within the hybrid domain. The positions of the Mg+ (★) and Ca+ (★) binding sites are indicated; B, Structure of the Mac-1 I-domain in the inactive state. The functionally important
α1 (blue) and α7 (red) helices are shown. C, Structure of the activated Mac-1 I-domain; note the magnesium ion (black dot) and the shifted position of the α7 helix. D, Schematic
structure of the external portion of αVβ3. In the crystal structure, the ligand binding site is turned towards the membrane (left); to the right is shown the stretched-out intermediate
afﬁnity form.
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[21]. One would envision that such a conformation could make ligand
binding more difﬁcult, and for this reason it was proposed that this
structure represented the inactive non-bound form, and that in the
active form, the integrin would “stand up” to be able to bind ligands
(Fig. 2D, right). Whether the integrin head in the active form really isturned towards the membrane has been a matter of controversy [28].
Crystallisation and subsequent soaking with an RGD peptide showed
that upon binding, only a minor structural change occurred [26]. The
bent conﬁgurationwas maintained. On the other hand, addition of the
same ligand to bent αVβ3 in solution induces leg extension and
conversion of the headpiece to the open conformation [29].Workwith
Fig. 3. Valency and afﬁnity modulations of integrins. By clustering of the integrins the avidity becomes high enough for functional adhesion (left). An intermediate afﬁnity may be
achieved by straightening out of the integrin, but high afﬁnity needs opening of the binding site (right). It should be pointed out that it is not known for sure that the integrins need to
straighten out in order to exhibit high afﬁnity.
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β chain is extended in the active integrin, as it can be observed by
using the KIM127 intermediate afﬁnity reporting antibody [30].
Using molecular dynamics it was recently reported that when the
RGD ligand is replaced by a ﬁbrinogen type III module, and allowed to
interact with the integrin headpiece, the hinge angle between the β I-
like domain and the hybrid domain in the headpiece of the αvβ3
integrin opens, resulting in the high afﬁnity form of the integrin head
[31]. Thus, it is becoming increasingly evident that the hybrid domain
in the β chain is critical for integrin activation, and a swing-out
movement of this activates integrins (see Fig. 3).
Negative stain electron microscopy with image averaging of
integrins has shown three overall conformations of the extracellular
domain and these correspond to a low afﬁnity, bent conformation (as
in the αVβ3 structure), an intermediate afﬁnity, extended formwith a
closed headpiece, and a high afﬁnity, extended form with an open
headpiece, which is induced by ligand mimetic compounds [32]. This
model is also supported by crystal structures of integrins that lack the
α I-domain, such as αIIbβ3 [32]. In these integrins, the ligand binds
directly to the β I-like domain, and causes a downward movement of
its α7 helix, similarly to what was described above for the integrin α
I-domains. This shift results in a swing-out movement of the β chain
hybrid and PSI domains and these domains act as a rigid lever that
transmits and ampliﬁes the motion, resulting in a separation of the α
and β legs and integrin extension [32]. On the other hand, the swing-
out movement of the upper β leg could readily occur if it were
preceded by extension of both legs. In conclusion, transmembrane
domain separation could occur as a later event during outside-in
integrin activation, or as a key early step during inside-out activation
[32].
Integrin conformation is dependent on the β chain, and an
allosteric regulation of the α chain I-domain by the β chain I-like
domain is essential. In particular, there is an invariant Glu (E310) in
the linker formed by the α7 helix and the β sheet 3 of the β2 propeller
domain, which is needed for I-domain activation [9,12,23,28]. This
glutamate may act as a ligand for the β I-MIDAS, which drags the
α7 helix from its resting position, and thus activates the integrin α
I-domain.
The importance of the close interaction between the α I-domain
and the β I-like domain is underscored by the ﬁnding of small
adhesion antagonist molecules, which bind to the β I-domains andinhibit the allosteric communication between I-domains [28]. Some
monoclonal antibodies to the β2 chain are also efﬁcient blockers of
adhesion and may act by inﬂuencing the α/β allosteric transitions
[33,34].
2.2. The transmembrane domains
Less is known about the α/β transmembrane regions. The
structure of αIIbβ3 integrin β chain includes a 30 amino acid long
transmembrane helix, which shows a tilt in lipid bilayers (bicelles)
with a snorkeling of Lys-716 out from the lipid core followed by
reinsertion in the membrane of the subsequent hydrophobic amino
acids Leu-717–Ile-721 [35]. The helix tilt angle may specify the α/β
transmembrane helix packing and control bidirectional signalling. In
the presence of full-length β3 cytoplasmic tail, helix propensity
continues into the cytosol and may be stabilised by talin binding. In
theα chain, the 29-residue transmembrane domain is formed by a 24-
residue α-helix (Ile-966–Lys-989). Also in this case, the terminal
residue is a lysine, which is snorkeling out of the membrane, followed
by a reversed segment (Gly-991, Phe-992, Phe-993) that packs against
the α-helix [36]. The Gly–Phe–Phe motif is fully conserved among
human α integrins, and it may play a crucial role for the integrin
transition from inactive to active: Phe/Ala double mutation leads to
receptor activation [37], showing that these residues are important to
keep the integrin in its resting state. Moreover, in the reported
cytoplasmic αIIbβ3 complex structure, which extends up to Lys-989,
the two Phe residues are in helical conformation [38], suggesting that
these residues might shift during integrins conformational changes.
In red cells glycophorin A displays an intramembrane GxxxG
sequence, which is important in homodimerisation [39,40]. This
conserved motif is also important in integrin α/β heterodimerisation,
which happens preferentially when the interaction is studied on
mammalian cell membranes [41]. Indeed, mutation of the two
glycines in the GxxxG motif markedly reduces the α/β transmem-
brane interactions and fails to activate the integrin [41]. Moreover,
there is a conserved valine in several integrin β chains (GVxxG) but
this is replaced by a threonine in β2 (T686). Importantly, when this
was mutated to valine, LFA-1 was activated and cells adhered to
intercellular adhesionmolecule-1 (ICAM-1) [42]. The integrin showed
relatively low afﬁnity because it did not bind to ICAM-3, and it did not
react with the intermediate afﬁnity reporting antibody KIM127.
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With the exception of the β4 integrin chain, the integrin
cytoplasmic domains are generally relatively short and all are devoid
of enzymatic activity (Fig. 4). Nevertheless, the cytoplasmic domains
play a pivotal functional role in integrin activity. The α chain
cytoplasmic domains show limited similarity, whereas the β chains
are well conserved, suggesting similar properties. In particular, our
knowledge of integrin cytoplasmic domains is based on the widely
studiedαIIbβ3. Plowand coworkers have studied byNMRspectroscopy
inwater solution the cytoplasmic peptides including the regions at the
transmembrane/cytoplasmic interphase. They found that proximal
portions of the α and β cytoplasmic parts are α-helical and associate
with each other [38,43]. The helices stretch from the membrane
interphase to Arg-998 in αIIb and to His-722 in β3 [44]. Importantly,
the distal part of theβ chainwas ordered, and the proximalα-helixwas
followed byaNPXY loop and a shortα-helix covering the residues from
Tyr-747 toThr-755. Very recent work shows that the cytoplasmic tail of
theαL integrin polypeptide forms a triple-helical structure; theα-helix
1 stretches from Lys-1093 to Met-1100, helix 2 from Ala-1112 to Glu-
1123, and helix 3 from Lys-1131 to Gly-1142. Helix 3 makes contacts
with both helix 1 and helix 2. Furthermore, helices 1 and 3 contact the
β2-tails in its N-terminal region, and the conformation of the β2 chain
changes after binding of activating talin [45]. Thus, there is vast data
supporting the view that a close association of α and β chains in theFig. 4. The cytoplasmic sequences of the human α and β integrin chains (β4 is not shown). T
sites are numbered. The conserved membrane proximal sequences in the α chain are marked
green and the threonine containing important phosphorylation sites in magenta.cytoplasmic region occurs in integrins in the resting state, whereas
chain separation results in activation of adhesion.
The GFFK(K)R sequence is well conserved in the α chains and is
important in keeping the integrins in a non-adhesive state. When this
motif is deleted or mutated, the integrins become activated [46,47]. It
has been proposed that the arginine (995 in αIIb) in this sequence
interacts with a juxtaposed aspartate (723 in β3) in the β chains [37].
Kim et al. [41] showed that the integrin domains preferentially form
heterodimers and the dimers are stabilised by the conserved
cytoplasmic arginine-aspartic acid interaction. Importantly, talin was
able to disrupt the association. Replacement of the αL and β2
cytoplasmic domains with salt bridge forming α-helical peptides
inactivates LFA-1, whereas replacement with peptides which cannot
dimerise causes activation. It is thought that this change in the
cytoplasmic domains is then translated to further changes in the
extracellular domains, resulting in integrin activation and ligand
binding. However, mutation of the salt bridge in vivo did not yield a
clear integrin phenotype, indicating that other events may occur [48].
Moreover, deletion of the GFFKR sequence in LFA-1 inmice, resulted in
increased LFA-1 activation and LFA-1-dependent adhesion. However,
the lack of LFA-1 deactivation resulted in impaired cell migration and
inﬂammatory cell recruitment in vivo [49]. There are also other
conserved sequences which are needed for integrin activity, for
example the two β chain NPxY(F) sequences are functionally
important [50] and are discussed below.he potential phosphorylation sites are marked in red. The established phosphorylation
in brown. The functionally important NPXY(F) sequences in the β chain are marked in
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Integrins bind to a large number of extracellular matrix molecules
and cell membrane proteins. A full description of these is not possible
here and falls out of the topic of this review, but the reader is referred
to published review articles [4–6]. TheαIIbβ3 integrin binds to several
ligands including ﬁbrinogen, ﬁbronectin and von Willebrand factor.
Several β1-family integrins bind to collagens, laminins, and ﬁbronec-
tin, but also to ﬁbrinogen. It should be pointed out that some integrins
show a high speciﬁcity for ligand binding, whereas others are more
promiscuous and bind several different types of ligands.
A key observation was the identiﬁcation of the RGD sequence in
ﬁbronectin and many other proteins, which is used as a common
binding site for integrins [51], while several collagen binding integrins
often recognise the characteristic tripeptide collagen repeats. The
tripeptide RGD is a key lead structure in the development of anti-
integrin competitive inhibitors [27,51,52]. Indeed, excess integrin
activity can be deleterious, and therefore there is much interest in
developing selective inhibitors of integrin activity. However, also
excessive integrin inhibition can be deleterious: a natural example is
provided by the snake toxins “disintegrins”, which contain the RGD
motif, and have devastating effects in humans [53].
Immunoglobulin superfamily members act as ligands for several
integrins, and the best characterised integrin ligands are VCAM-1
(Vascular Cell Adhesion Molecule) and the ICAMs. VCAM-1 binds to
α4β1, αVβ3 and α4β7, whereas the leukocyte-speciﬁc CD11/CD18
integrins (including LFA-1 and Mac-1) bind to ICAMs [54,55]. Five
ICAMs are known: ICAM-1–ICAM-5 [6] (Fig. 5). ICAM-1 is expressed in
many tissues including leukocytes and endothelial cells, and its
expression is easily up-regulated upon cellular activation, for example
by cytokines during inﬂammation [56]. ICAM-2 is found in leukocytes
and endothelial cells [57,58], but it is more resistant to up-regulation
[59]. However, it shows increased expression in malignant tissues
[60]. ICAM-3 is expressed in leukocytes and is primarily important in
immune responses [61,62]. ICAM-4 is red cell-speciﬁc [63], and recent
work indicates that it may have a role in the removal of senescent cells
by spleen macrophages [64]. ICAM-5 is solely expressed in brain
neurons [65], and it shows both heterophilic and homophilic binding
[66,67]. It strongly induces dendrite outgrowth [67], and upon
glutamate receptor activation it is cleaved by the matrix metallopro-Fig. 5. Schematic structures of ICAMs. Similar Ig-like domains are colour coded. ICAM-1 a
or tetramer.teinases MMP-2/-9 [68]. Surprisingly, the soluble ICAM-5 fragment in
turn causes inhibition of T lymphocyte activation, opposite to that of
ICAM-1 [69]. This interesting molecule has recently been reviewed
[70].
Leukocyte integrins are recognised therapeutic targets in various
diseases, and integrin blocking monoclonal antibodies (natalizumab
againstα4 integrins and efalizumab against LFA-1) are already used in
the clinic against multiple sclerosis and psoriasis [71,72]. Also small
molecule antagonists against leukocyte integrins are being developed.
Interestingly, the statins, which are widely used for lowering
cholesterol levels, have proved efﬁcient inhibitors of leukocyte
adhesion [73,74]. As an example, lovastatin binds at a crevice between
the F-strand and the α I-domain of LFA-1 and inhibits allosteric
movements [9]. Several monoclonal adhesion blocking antibodies
bind to the β chains and they may act by inhibiting the allosteric
movements needed for integrin activation [75]. Because phosphoryla-
tion of integrin cytoplasmic tails show functional effects it would be
important to develop drugs that speciﬁcally interferewith the integrin
phosphorylations. Such drugs could affect cell adhesion, movement or
other integrin-dependent functions [76]. However, little has yet been
done in this ﬁeld.
Leukocyte adhesion cannot be inhibited by compounds containing
the RGD sequence, but longer peptides to recognition sites in ICAM-
molecules or microbe-derived ICAM-1 inhibitors [77,78] do show
inhibitory activity [79,80]. Soluble ICAM-1 and -2 are found in plasma
and they show inhibition of adhesion, but are not very efﬁcient, due to
low afﬁnity for the integrins. A promising approach could be to disrupt
the association between the matrix metalloproteases and integrins
[15,16].
Recently, it was found that the Del-1 protein is an important
endogenous inhibitor of leukocyte adhesion [81]. The Del-1 protein is
a secreted protein expressed by endothelial cells in immunoprivileged
tissues, such as the brain, the eye, and the lung. Although a secreted
molecule, Del-1 is absent from plasma and is rather localised to
endothelial cells and/or the extracellular matrix [81,82]. In fact, it
binds to the β2 integrins (LFA-1, Mac-1) and when coated on plastic,
leukocytes adhere to the protein. However, leukocyte binding to
ICAM-1 is inhibited when both Del-1 and ICAM-1 are present. Del-1
knockout mice show a strong activation of adhesion and of
inﬂammatory cell recruitment [81].nd ICAM-3 are dimers, ICAM-2 and ICAM-4 monomers. ICAM-5 may exist as a dimer
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Because integrins perform a number of different functions
including adhesion and signalling in two directions we could
anticipate that several types of mechanisms must exist to achieve
these goals. Furthermore, it is obvious that integrins in some cases
must be able to react rapidly, whereas in other instances this is not
that important. An example of the former is the adhesion of
leukocytes to endothelial cells in blood vessels [83,84], whereas an
example of a slower reaction could be the formation of the
immunological synapse between a T cell and an antigen-presenting
cell during an immune response and subsequent signalling [85].
As discussed in the section on integrin structure, there is ample
proof that conformational changes occur in integrins. These involve
changes in integrin-binding afﬁnity. Another mechanism for integrin
activation includes clustering, so that an increased valency results in
increased ligand binding through higher avidity. Obviously, combina-
tions of these two major mechanisms are possible (Fig. 3).
4.1. Outside-in activation involves changes in integrin
conformation — allosteric regulation
Several experiments show that ligand binding to the external
domains of integrins induce conformational changes, which may
increase ligand afﬁnity. Subsequently, signals may be generated
through alterations in the cytoplasmic domain structures.
Most molecular work done on outside-in integrin activation deals
with the leukocyte and platelet integrins. In particular, β2 integrins
constitute excellent models for research on integrin regulation. There
are several reasons for this: leukocytes are easily obtained, the cells
grow in suspension, a number of cell lines are available and for
example T lymphocytes exist in a truly resting state, but can easily be
activated by both outside-in and inside-out activations. Furthermore,
a vast amount of structural and functional information is available on
β2 integrins, notably LFA-1 and Mac-1. In these integrins, the I-
domain, which forms the ligand binding site, is of pivotal importance.
The binding of ICAM-5 to the LFA-1 I-domain has recently been
studied in atomic detail. Upon binding a remarkable outward
movement of the α7 helix was observed [86]. This resulted in the
replacement of the corresponding α7 helix from a neighbouring I-
domain into the α7 helix position, but in an upside-down conﬁgura-
tion. This α7 helix replacement was further propagated, resulting in a
large I-domain/ICAM-5 cluster. In this way, a weak initial interaction
between the integrin and a ligand can result in the formation of large
ligand/receptor aggregates. Whether this occurs with the whole
integrin and in the cell membrane is not known, but integrin
clustering (valency increase) is certainly a major mechanism of
adhesion. Theα2β1 integrin also contains an I-domain and the binding
to a collagen triple-helical peptide has been studied at the atomic level
[87], showing similar mechanisms.
It is becoming increasingly apparent that the integrin β polypep-
tides have an important role in integrin activity regulation, and also in
ligand binding. As discussed above, the β I-like domain regulates
allosterically the α I-domain ligand afﬁnity. In particular, the
ADMIDAS site interaction with the MIDAS site does not occur upon
activation, allowing remodeling of the ligand binding site [9,12].
Stabilisation of the α7 helix structure impairs integrin afﬁnity
regulation and leads to a LAD-I phenotype. This was obtained by
making the mutation N329S in the β I-like domain [88].
The outside-in activation propagates signals to the cytoplasm. In
elegant experiments Springer and coworkers have studied the
signalling by using chimeric αL-cyan ﬂuorescent proteins and β2-
yellow ﬂuorescent proteins [89]. When transfected into cells the
cytoplasmic ﬂuorescent proteins were closely associated giving
positive FRET signals. Upon outside-in activation using Mn+, ICAM-
1, or an LFA-1 activating antibody, the FRET signals disappeared,evidently due to increased distances between the cytoplasmic integrin
domains.
4.2. Interactions between integrin cytoplasmic domains and intracellular
factors regulate integrin activity and ligand binding: inside-out activation
From where do the structural changes explained above originate?
In most cases of integrin activation, signals originate from various cell
surface receptors, which propagate them into the cell. Intracellular
signalling pathways leading from receptors to integrin activation have
been discussed in several recent reviews [7–12,90], and the reader is
referred to these for further information. For the β2 integrins such as
LFA-1, these events have been extensively studied in T cells, where
integrin inside-out activation can be initiated by ligation of the T cell
receptor or chemokine receptors.
More proximal to the integrin receptor, it is thought that structural
changes/valency changes in the integrin are mediated by the
regulated interaction of the integrin cytoplasmic domains with
intracellular factors. Indeed, a large number of proteins have been
described to directly interact with integrin cytoplasmic domains,
including cytoskeletal proteins (talin, ﬁlamin, alpha-actinin, kindlins),
small G proteins and GEFs (cytohesin), adaptor proteins (14-3-3),
kinases (protein kinase D), and even transcriptional coactivators (JAB-
1). At least some of these proteins have overlapping binding sites in
the integrin cytoplasmic domains; thus, spatiotemporal regulation of
these interactionsmust be important. Beloware described some of the
factors binding to integrin cytoplasmic tails.
4.3. Important cytoplasmic integrin regulators
Talin is a 270 kDa cytoplasmic protein with a globular head and a
ﬂexible rod region [91]. Importantly, the head region of talin can
activate integrins. The head contains a FERM domain (Protein 4.1,
Ezrin, Radixin, Moesin) which has F1, F2 and F3 subdomains. The
interaction of the F3 domainwith the β3 integrin has been extensively
studied, and the structure of the F3 domain with an integrin
cytoplasmic peptide has been determined [92,93]. The head domain
binds to the proximal NPXY (F) in integrin β chains, with the tyrosine
inserting into a hydrophobic product in F3, as does Trp-739 from the
β3 integrin. The integrin peptide adopts a β-strand conformation
followed by a reverse turn [92]. Additionally, the F3 domain interacts
hydrophobically with the membrane proximal α-helical region of the
integrin cytoplasmic domain [93,94], and is thus positioned to affect
the activation state of the integrin by perhaps affecting the association
between the α and β integrin polypeptides. Importantly, disruption of
the talin gene in platelets leads to impaired integrin activation,
demonstrating the crucial role of this protein in integrin regulation
[95].
It has now been shown that the talin head domain has a Kd of 0.1–
0.5 μM for the β2-tail [45,96] whereas the Kd for the afﬁnity ofαL to β2
is 2.6 μM [45]. This ﬁnding explains the fact that talin is able to disrupt
the αL and β2 association. It is thought that talin is recruited to the
integrin tails by the Rap1-GTP-interacting-adaptor molecule (RIAM).
Indeed, RIAM overexpression stimulates αIIbβ3, and induces adhe-
sion, whereas a knock-down blocks it [97]. The G protein exchange
factor CalDAG-GEF1 is also needed for Rap1 activation, and in this way
it participates in the Rap1-talin activation of integrins [98]. For
example, in the rare LAD-I variant (LAD-III) syndrome CalDAG-GEF1 is
often mutated and integrin signalling is impaired [99].
The kindlin family of proteins consists of three members, kindlin-
1,-2 and -3 [100]. Kindlin-1 is mutated in the Kindler syndrome, where
skin blistering occurs due to failure of actin function in keratinocytes.
Kindlin-2 is widely expressed and interacts with integrin-linked-
kinase (ILK) and migﬁlin [101]. Kindlin-3 is conﬁned to hematopoietic
cells [102] and may regulate cell apoptosis by acting as a transcrip-
tional repressor in NF-kB signalling [103]. Interestingly, patients who
Fig. 7. The crystal structure of the ﬁlamin domain 21 (green) binding region in complex
with the β2 peptide. The important Thr-758 is shown. When this becomes
phosphorylated hydrophobic interactions are disturbed and there is no space for the
peptide in the ﬁlamin binding site and binding becomes impossible.
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their kindlin-3 gene and in most cases [104], but not always, in their
CalDAG-GEF1 gene [105]. This shows that the syndrome is due to
defective kindlin-3 [104]. Kindlin-2 is known to bind to the T-759ST-
NITY region of the β3 integrin polypeptide and acts synergistically
with talin in integrin activation [106] and the binding site for kindlin-3
is in the same region [102].
Similarly to talin, α-actinin can also bind both actin and integrin β
chains. The binding site is located in themembrane proximal region of
the β2 integrin polypeptide, while the membrane distal portion has an
inhibitory effect on these interactions [107] (Fig. 6). Recently, it has
been shown how α-actinin links LFA-1 to the cytoskeleton, and
disruption of such binding results in loss of cell spreading and
migratory speed. Furthermore, α-actinin co-localised and could be
immune precipitated with KIM127 positive LFA-1 molecules, which
shows that intermediate afﬁnity integrins and α-actinin form a
complex [108].
Filamin is a large cytoskeletalmolecule that has also been shown to
bind to integrin β chains [109]. Its binding site in the integrin is
partially overlapping with talin (Fig 6) and indeed, ﬁlamin appears to
be a negative regulator of at least β7 and β2 integrin ligand binding
and of cell migration [110]. The crystal structure of the integrin-
binding Ig-like domain (domain 21) of ﬁlamin in complex with β7 and
β2 integrin peptides has been solved [96,111], and shows that the
integrin peptide forms extended β-strands that interact with strands C
and D in the Ig-like domain-21 of ﬁlamin (Fig. 7).
The cytohesins 1–4 are nucleotide exchange factors (GEF) for the
ARF family of small G proteins [112]. Cytohesin-1 binds through its
central domain to the proximal part of the β2-subunit, whereas its
pleckstrin homology domain interacts with the plasma membrane
lipids. The β2-interaction results in up-regulation of LFA-1 activity.
GEF activity is not needed in this context [113], but it is required for
cell spreading. Cytohesin-3 has a similar activity as cytohesin-1 [114],
whereas cytohesin-2 regulates cell motility [115,116]. Cytohesin-1 is
also implicated in Mac-1 inside-out signalling through the CD14/Toll-
like receptor in monocytes [117].
The 14-3-3 proteins are small dimeric adapter proteins that bind to
Ser/Thr phosphorylated sequences in proteins and alter protein
localisation or activity. Phosphorylation of β2 polypeptides on Thr-
758 results in recruitment of 14-3-3 proteins [118]. 14-3-3 only binds
to the phosphorylated peptide in the well characterised binding site
between 14-3-3 α-helices E and F [96]. This interaction is functionally
important, because when it is inhibited by a T/A mutation in the
integrin, adhesion to ICAM-1 is reduced [118]. The inhibition can also
be achieved by using a construct that blocks the phosphopeptide
binding site in 14-3-3. Inhibition of the 14-3-3/integrin-binding
efﬁciently impairs cell spreading on ICAM-1. The Cbl-b protein is an
adaptor protein and a ubiquitin ligase, which has been shown to affect
leukocyte adhesion. T cells deﬁcient in Cbl-b showed enhanced
adhesion to ICAM-1 [119]. Importantly, Cbl-b deﬁciency results in
increased phosphorylation of T758, followed by enhanced binding of
14-3-3 proteins and increased LFA-1 activity [120]. Interestingly, the
threonines 758–760 in β2 are also essential for the accumulation ofFig. 6. Overlapping binding sites for cytoskeletal proteins in the β2 cytoplasmic
segment. The functionally important threonine-758 residue is shown in bold.
Phosphorylation of this residue enables binding of 14-3-3 proteins but inhibits ﬁlamin
binding.the small G protein Rho in its active GTP form at Mac-1 containing
phagosomes, showing that also other β2 integrins may be regulated by
this phosphorylation event [121].
Importantly, these structural studies have shown that the integrin
cytoplasmic tails may adopt different conformations depending on
which cytoplasmic partner is bound to it. Additionally, the kindlin
studies have revealed that also other proteins than talin may play
important roles in integrin activation in vivo.
Integrin inside-out and outside-in activations are regulated by
phosphorylations. Integrin directional signalling is regulated by
cytoplasmic proteins. How are these molecular interactions with
integrin cytoplasmic domains then regulated? At least competition
and phosphorylation appear to regulate binding of cytoplasmic
molecules to the integrin tails. This is an area of research which is
still relatively underexplored, but details of which are currently
emerging. The most common way to regulate protein (enzyme)
activities is by phosphorylation and dephosphorylation of serine/
threonine and tyrosine residues. A characteristic feature of this
modiﬁcation is the possibility of rapid reactions, especially when
compared to the slower changes regulated at the transcription and
translation levels. Although integrin phosphorylation has been
studied for more than 20 years, major developments occurred only
recently [76].
4.4. β2 integrin chain phosphorylation
The cytoplasmic sequences of the α and β chains of LFA-1, Mac-1,
αxβ2 and αDβ2 are shown in Fig. 4 with the potential phosphorylation
sites marked in red. From early on it was noted that α chains are
constitutively phosphorylated, whereas the β chain is not [122–125].
Both phorbol esters and T cell receptor antibodies could induce
phosphorylation of threonine residues in the β tail [[126–129]. These
threonines are important for adhesion to ICAM-1 [125]. In addition,
Ser-745 is phosphorylated and several isoforms of protein kinase C can
phosphorylate the β2 chain cytoplasmic peptide in vitro [128]. Ser-756
is strongly phosphorylated when T cells are activated with phorbol
439C.G. Gahmberg et al. / Biochimica et Biophysica Acta 1790 (2009) 431–444esters [125], but not by activation of the T cell receptor [129]. This
could mean that the serine phosphorylation is an experimental
artifact or it is involved in T cell functions not related to antigen
activation. Tyr-735 is phosphorylated in interleukin-2 treated natural
killer cells [130], and also in neutrophils after binding to collagen
[131]. Whether this phosphorylation results in recruitment of
cytosolic proteins is not known. A schematic view of the T cell
receptor initiated phosphorylation of the β2 chain is shown in Fig. 8.
4.5. αL and αM integrin polypeptide phosphorylations
The phosphorylation site in αL turned out to be Ser-1140 [118], and
interestingly cellular activation through chemokines, or outside-in
activation through soluble ICAM-2 or Mg+ treatment was attenuated
in S1140A mutated cells. Furthermore, the αL non-phosphorylated
variant can form an integrin heterodimer, but themutation affected its
ability to induce conformational changes in the integrin. Thus the
S1140Amutation resulted in inability to bind soluble ligand (ICAM-1),
and the activation epitope for the monoclonal antibody Mab24 was
not induced by the activating antibody MEM83 [118]. However, use of
the KIM127 antibody has shown that the ability to form an extended
form is not lost by the mutation (unpublished). These results indicate
that rearrangements within the αL I-domain need phosphorylation of
Ser-1140 to become fully active.
Further work showed that αM phosphorylation takes place on Ser-
1126. Mutation of this residue resulted in impairment of transfected
cells to leave the blood. Whereas wild-type cells largely accumulatedFig. 8. Phosphorylation of the β2 chain. Phosphorylation of β2 through the T cell receptor r
modulations.in the lungs and spleen of mice injected for a short time with human
cells, Ser-1126 mutated cells remained in the circulation [132]. In
contrast to the situation with LFA-1, Mac-1 extension upon activation
did not occur in S1126 mutated cells as detected with KIM127. This
result shows that the β2 integrins are differently regulated by
cytoplasmic phosphorylations.
4.6. Phosphorylation of β1 and β3 integrins
As compared to the extensive work on various aspects of β2 and β3
integrins, there are relatively few studies on the phosphorylations of
β1 integrins. The β chains contain the two functionally important
cytoplasmic NPxY/F sequences (Fig. 4). In β1 they are located at
residues N-780PIYand N-792PKYand in β3 at N-744PLYand N-756ITY.
The β1 tyrosine residues may be phosphorylated, but phosphoryla-
tions do not seem important in this case, because mutations to
phenylalanines have no effect. However, mutations to alanines
resulted in β1-null phenotypes in vivo [48].
Thr-788, which corresponds to the ﬁrst threonine in the β2-
threonine triplet is important for β1 integrin function [133]. Mutation
to alanine reduced cell attachment to ﬁbronectin, whereas the
phosphorylation-mimicking mutation T788D was similar to wild-
type integrins. However, it induced an increased number of focal
contacts and the cells migrated more slowly.
The α4β1 integrin is important for leukocyte migration and
inﬂammation. Ser-988 in the α chain is phosphorylated, possibly by
protein kinase A [134,135]. Mutation of this residue to alanine reducedesults in downstream events affecting integrin activation through avidity and afﬁnity
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inhibited cell migration and promoted cell spreading. This couldmean
that both phosphorylation and dephosphorylation at Ser-988 are
functionally important. The phosphorylated form of α4β1 preferen-
tially located to the leading edge of cells where active protein kinase A
is present, indicating that localised activation of α4β1 takes place
through a local activation of the protein kinase.
Outside-in binding of αIIbβ3 ligands resulted in further activation
and tyrosine phosphorylation of the tyrosines in the two β3 NPxY
sequences [136]. These phosphorylations induced signalling and
platelet aggregation. The tyrosines are needed for cell spreading and
transfer of the integrins to focal adhesion sites [50]. The β3
phosphorylated Tyr-759 made the β3 chain resistant to calpain
cleavage, whereas the dephosphorylated chain could be cleaved, and
this inactivated integrin signalling and cell spreading [137]. The β3
polypeptide in αVβ3 is evidently phosphorylated when bound to
vitronectin but not to ﬁbronectin [138,139], which shows that the
ligand may affect tyrosine phosphorylation.
4.7. Phosphorylation of integrin tails affects cytoskeletal interactions
and signalling
In the previous chapter we have described phosphorylation in the
cytoplasmic tails of integrins. But how do the phosphorylations
mediate further cellular effects? Recent work has partially elucidated
the mechanisms. It is evident that phosphorylation enables integrins
to regulate their interactions with adaptor and cytoskeletal proteins,Fig. 9. A schematic and partially hypothetical view of LFA-1 activation. In the resting state (le
through the T cell receptor, talin may be cleaved by activated calpain, which results in bindin
Then phosphorylation of β2 (Thr-758) results in 14-3-3 binding, displacement of talin an
clustering. The integrin is here shown in extended forms.resulting in subsequent downstream effects. A number of cytoplasmic
proteins affect integrin-dependent signalling and adhesion, and our
current picture of these events is still a simpliﬁed version which is far
from complete.
Thr-758 phosphorylation directly regulates the binding of 14-3-3
proteins andﬁlamin to theβ2 integrin cytoplasmic domain.14-3-3 only
bound to the phosphorylated form, while ﬁlamin only bound to the
non-phosphorylated form of the integrin [96] (Fig. 6). X-ray crystal-
lography experiments clearly showed how phosphorylation of the tail
works as a molecular switch to change the binding [96] (Fig. 7). When
Thr-758 was phosphorylated, ﬁlamin binding was inhibited because
the hydrophobic interaction between ﬁlamin and Thr-758 in the
integrin was disrupted. Talin binding was not directly affected by Thr-
758 phosphorylation of LFA-1, but 14-3-3 and talin binding sites in the
integrin are partially overlapping, and 14-3-3 binding out-competed
the binding of talin to the integrin cytoplasmic tail [96].
Thus both phosphorylation and competition between these
proteins regulate interactions with the integrin cytoplasmic domains.
Additional complexity is added by other cytoplasmic proteins. Recent
work shows that the adaptor protein migﬁlin binds to ﬁlamins-1, -2
and -3 in a very similar mode as the β2 and β7 integrin tails [140]. It
dissociated ﬁlamin from integrin β-tails, and promoted talin binding
and integrin activation [141].
A conceptually similar switch of integrin activation as for β2-
ﬁlamin/talin/14-3-3 was recently reported for the β3 integrin chain
[142]. Talin bound well to the β3 cytoplasmic peptide, but upon
phosphorylation of Tyr-747 in the proximal canonical NPXY motif inft) ﬁlamin is bound to the integrin and the ligand binding site is closed. Upon activation
g of the talin head to the integrin cytoplasmic tails and separation of the integrin chains.
d activation of Rac1/Cdc42, which affect the actin cytoskeleton resulting in integrin
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here phosphorylation of the integrin regulates the binding of
cytoplasmic factors to the integrin tail, demonstrating that this may
be a universal principle in the regulation of integrin signalling.
The phosphorylation of the β2 integrin polypeptide at Thr-758
further activates integrin inside-out signalling. This was seen by
subsequent activation of the small G proteins Rac1 and Cdc42 [143].
Activation of Rac1 is known to induce the formation of actin polymers
resulting in lamellipodia and membrane rufﬂes [144]. Activation of
Cdc42 in turn results in the formation of ﬁlopodia [144]. 14-3-3
proteins do not bind to these G proteins directly, and therefore there
must exist adaptor molecules between 14-3-3 and the G proteins. One
possible candidate is Vav-1. Upon activation of integrin signalling,
Vav-1 was phosphorylated and cell spreading was induced [145].
Consistently, Vav-1/Vav-3-deﬁcient neutrophils displayed impaired
β2 integrin-dependent adhesion and spreading [146]. Another
candidate is the Rac1 nucleotide exchange factor Tiam1. Tiam1 can
activate Rac1, but not Cdc42 [147,148] and it is involved in T cell
trafﬁcking [149]. The Cdc42 protein can induce cell polarity after β1
integrin activation, because in migrating astrocytes an RGD peptide
completely inhibited Cdc42. Furthermore, Cdc42 recruited a partition-
ing defective polarity complex (Par) containing PKC( [150]. A
schematic view of these events is shown in Fig. 9.
The functional signiﬁcance of the other phosphorylation sites in β2
is not well understood. Ser-745 is phosphorylated in β2 [128], and this
phosphorylation is induced after treatment of cells with LFA-1
antibodies or the ligand ICAM-2 [151]. The phosphorylation resulted
in disengagement of the transcriptional activator JAB-1 from LFA-1,
and this triggered further downstream signalling events. This would
thus be an example of outside-in signalling where phosphorylation is
important.
The αL phosphorylation on Ser-1140 and the Ser-1126 phosphor-
ylation of αM are functionally important, but little is known about
which kinases are involved or how the phosphorylations affect
function. The integrin α chain phosphorylations affect integrin
conformations as shown by monoclonal reporter antibodies and
increased afﬁnity of integrins for ligands. A constitutively active Rap1
G protein has been shown to activate T cells and to induce adhesion to
ICAM-1 [152,153]. Interestingly, it could not activate the αL phosphor-
ylation site mutant [118]. Rap1 in turn binds to the RAPL protein [154].
RAPL was found to regulate theMst1 protein kinase and they formed a
complex at the leading edge of cells [155]. Mst1 is needed for the
downstream effects of RAPL. Rap1 requires Cdc42 activity and Tiam1
has been found to associate with Rap1 and the Par complex [156]. In
migrating T cells, Tiam1 and the Par complex are required to induce
polarity with LFA-1 at the leading edge. Thus there may exist a
crosstalk between the αL and β2 phosphorylations through these G
proteins and nucleotide exchange factor proteins.
Paxillin is an adaptor protein, which binds to theα4 chain resulting
in increased cellular migration but reduced spreading [134,157]. The
Ser-988 phosphorylation inhibited paxillin binding. When the residue
was mutated to aspartic acid, which at least partially mimics
phosphorylation, the paxillin binding was inhibited and the cells
showed effects similar to that of the phosphorylated integrin. When
mutated to alanine, cell migration was reduced, due to paxillin
binding. These results indicate that phosphorylation/dephosphoryla-
tion at Ser-988 is needed for physiological cell migration.
4.8. Different protein phosphatases are important in integrin regulation
The phosphatase 2A dephosphorylates Ser/Thr residues and is
blocked by okadaic acid and calyculin A. It can bind to the proximal
cytoplasmic sequence KVGFFKR in αIIb and interestingly it blocks
αIIbβ3 signalling [158]. Binding of collagen to the α2β1 integrin
activated the 2A phosphatase, which resulted in dephosphorylation of
the Akt and glycogen synthase kinase 3β [159]. On the other hand,activation of the tyrosine phosphatase TCPTP by the α1β1 integrin,
down-regulated epidermal growth factor receptor signalling [160].
These results further support the view that not only kinases, but also
phosphatases are involved in regulation of integrin activity.
The fact that inside-out signalling results in activation of integrin-
binding to ligands, and initially weak ligand binding from the outside
can result in stronger binding and adhesion (see ICAM-5 [86]), shows
that these two events are intimately connected. This would mean that
in many instances a functioning adhesion complex is built up from
integrin ligand interactions with integrins up-regulated both by
changes in afﬁnity and avidity.
In order to understand complex biological phenomena, scientists
have often turned to simpliﬁed experimental setups. This certainly
also holds true in integrin research: much work has been done with
puriﬁed integrins, or I-domains and their ligands. This type of research
has been very rewarding and yielded to a vast amount of useful data.
However, it is becoming increasingly apparent that cellular adhesion is
unusually complex, and in order to be able to make meaningful
conclusionswe have to study evenmore inmolecular detail the events
occurring at the cellular and organism levels. It is also important to
include more temporal aspects in adhesion research, especially when
various intracellular proteins compete for integrin-binding during
activation. Many of them act indirectly through regulation of integrin-
mediated adhesion, and therefore the adhesion ﬁeld is becoming even
more challenging to understand. The use of partially reconstituted
systemsmay turn out necessary, but we have to develop newmethods
and increasingly turn to animal models. This will be a long, but
interesting, scientiﬁc journey.
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LFA-1: leukocyte function associated antigen (αLβ2, CD11a/CD18)
ICAM: intercellular adhesion molecule
Mac-1: macrophage antigen-1 (αMβ2, CD11b/CD18)
I-domain: intervening domain (A-domain)
MMP: matrix metalloprotease
LAD: leukocyte adhesion deﬁciency
